Tokyo Tape
Sign in
← M3

Half-year report · Q2

2413.TEDINET S100UO9S
Period2024-04-01 → 2024-09-30
Filed2024-11-08
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
MetricValuePeriodScopeSource row
Revenue¥124.8bn2024-04-01 → 2024-09-30Cons.Revenue IFRS
Revenue¥238.9bn2023-04-01 → 2024-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥115.8bn2023-04-01 → 2023-09-30Cons.Revenue IFRS
Operating income¥29.0bn2024-04-01 → 2024-09-30Cons.Operating profit loss IFRS
Operating income¥34.6bn2023-04-01 → 2023-09-30Cons.Operating profit loss IFRS
Profit before tax¥29.1bn2024-04-01 → 2024-09-30Cons.Profit loss before tax IFRS
Profit before tax¥68.8bn2023-04-01 → 2024-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥37.3bn2023-04-01 → 2023-09-30Cons.Profit loss before tax IFRS
Net income (owners)¥17.3bn2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥45.3bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥23.4bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income¥19.6bn2024-04-01 → 2024-09-30Cons.Profit loss IFRS
Net income¥25.1bn2023-04-01 → 2023-09-30Cons.Profit loss IFRS
Total assets¥491.5bnat 2024-09-30Cons.Assets IFRS
Total assets¥490.8bnat 2024-03-31Cons.Assets IFRS
Total assets¥461.0bnat 2023-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥127.0bnat 2024-09-30Cons.Liabilities IFRS
Total liabilities¥124.1bnat 2024-03-31Cons.Liabilities IFRS
Net assets / equity¥364.4bnat 2024-09-30Cons.Equity IFRS
Net assets / equity¥366.7bnat 2024-03-31Cons.Equity IFRS
Net assets / equity¥345.2bnat 2023-09-30Cons.Equity IFRS
Net assets / equity¥309.5bnat 2023-03-31dCons.Equity IFRS
Equity (owners)¥349.5bnat 2024-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥351.9bnat 2024-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥331.6bnat 2023-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥148.1bnat 2024-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥149.7bnat 2024-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥135.1bnat 2023-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥118.3bnat 2023-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥23.6bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥58.3bn2023-04-01 → 2024-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥26.8bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥11.3bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥39.5bn2023-04-01 → 2024-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥28.3bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥12.6bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥9.4bn2023-04-01 → 2024-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥15.3bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥25.472024-04-01 → 2024-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥66.682023-04-01 → 2024-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥34.472023-04-01 → 2023-09-30Cons.Basic earnings loss per share IFRS
EPS (diluted)¥25.42024-04-01 → 2024-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥66.632023-04-01 → 2024-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥34.452023-04-01 → 2023-09-30Cons.Diluted earnings loss per share IFRS
Equity ratio71.1%at 2024-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio71.7%at 2024-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio71.9%at 2023-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 54
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30−¥1.9bn
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30−¥1.9bn
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥1.7bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue2024-04-01 → 2024-09-30¥11.6bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue external2024-04-01 → 2024-09-30¥11.6bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥18m
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentsegment profit2024-04-01 → 2024-09-30¥4.1bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue2024-04-01 → 2024-09-30¥11.9bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue external2024-04-01 → 2024-09-30¥11.8bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥100m
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentsegment profit2024-04-01 → 2024-09-30¥1.9bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue2024-04-01 → 2024-09-30¥42.5bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue external2024-04-01 → 2024-09-30¥40.7bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥1.7bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentsegment profit2024-04-01 → 2024-09-30¥14.6bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue2024-04-01 → 2024-09-30¥38.0bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue external2024-04-01 → 2024-09-30¥38.0bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥28m
jpcrp040300-q2r_E05425-000Overseasreportable segmentsegment profit2024-04-01 → 2024-09-30¥6.6bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue2024-04-01 → 2024-09-30¥21.6bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue external2024-04-01 → 2024-09-30¥21.6bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥6m
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentsegment profit2024-04-01 → 2024-09-30¥3.0bn
—segment totalrevenue2024-04-01 → 2024-09-30¥125.6bn
—segment totalrevenue external2024-04-01 → 2024-09-30¥123.7bn
—segment totalrevenue intersegment2024-04-01 → 2024-09-30¥1.9bn
—segment totalsegment profit2024-04-01 → 2024-09-30¥30.3bn
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥1.8bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥1.8bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30¥125m
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue2023-04-01 → 2023-09-30¥9.0bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue external2023-04-01 → 2023-09-30¥9.0bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥21m
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentsegment profit2023-04-01 → 2023-09-30¥3.3bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue2023-04-01 → 2023-09-30¥13.8bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue external2023-04-01 → 2023-09-30¥13.6bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥215m
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentsegment profit2023-04-01 → 2023-09-30¥3.6bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue2023-04-01 → 2023-09-30¥45.5bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue external2023-04-01 → 2023-09-30¥44.0bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥1.5bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentsegment profit2023-04-01 → 2023-09-30¥18.4bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue2023-04-01 → 2023-09-30¥32.7bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue external2023-04-01 → 2023-09-30¥32.6bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥11m
jpcrp040300-q2r_E05425-000Overseasreportable segmentsegment profit2023-04-01 → 2023-09-30¥7.3bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue2023-04-01 → 2023-09-30¥15.3bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue external2023-04-01 → 2023-09-30¥15.3bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥7m
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentsegment profit2023-04-01 → 2023-09-30¥1.8bn
—segment totalrevenue2023-04-01 → 2023-09-30¥116.4bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥114.6bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥1.7bn
—segment totalsegment profit2023-04-01 → 2023-09-30¥34.4bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 642
ItemContextValueUnit
Independent auditors report consolidated (text)FilingDateInstantText · Plus
Audit firm1 consolidatedFilingDateInstant
Original text (Japanese)PwC Japan有限責任監査法人
Cpa1 audit firm1 consolidatedFilingDateInstant
Original text (Japanese)加藤正英
Cpa2 audit firm1 consolidatedFilingDateInstant
Original text (Japanese)村田賢士
Number of submissionFilingDateInstant1
Revenue IFRS (5-year summary)Prior1YTDDuration115795000000JPY
Revenue IFRS (5-year summary)CurrentYTDDuration124819000000JPY
Revenue IFRS (5-year summary)Prior1YearDuration238883000000JPY
Profit loss before tax IFRS (5-year summary)Prior1YTDDuration37322000000JPY
Profit loss before tax IFRS (5-year summary)CurrentYTDDuration29074000000JPY
Profit loss before tax IFRS (5-year summary)Prior1YearDuration68840000000JPY
Profit loss attributable to owners of parent IFRS (5-year summary)Prior1YTDDuration23406000000JPY
Profit loss attributable to owners of parent IFRS (5-year summary)CurrentYTDDuration17294000000JPY
Profit loss attributable to owners of parent IFRS (5-year summary)Prior1YearDuration45271000000JPY
Comprehensive income attributable to owners of parent IFRS (5-year summary)Prior1YTDDuration35721000000JPY
Comprehensive income attributable to owners of parent IFRS (5-year summary)CurrentYTDDuration11291000000JPY
Comprehensive income attributable to owners of parent IFRS (5-year summary)Prior1YearDuration60490000000JPY
Equity attributable to owners of parent IFRS (5-year summary)Prior1QuarterInstant331622000000JPY
Equity attributable to owners of parent IFRS (5-year summary)CurrentQuarterInstant349533000000JPY
Equity attributable to owners of parent IFRS (5-year summary)Prior1YearInstant351915000000JPY
Total assets IFRS (5-year summary)Prior1QuarterInstant461018000000JPY
Total assets IFRS (5-year summary)CurrentQuarterInstant491469000000JPY
Total assets IFRS (5-year summary)Prior1YearInstant490780000000JPY
Basic earnings loss per share IFRS (5-year summary)Prior1YTDDuration34.47
Basic earnings loss per share IFRS (5-year summary)CurrentYTDDuration25.47
Basic earnings loss per share IFRS (5-year summary)Prior1YearDuration66.68
Diluted earnings loss per share IFRS (5-year summary)Prior1YTDDuration34.45
Diluted earnings loss per share IFRS (5-year summary)CurrentYTDDuration25.40
Diluted earnings loss per share IFRS (5-year summary)Prior1YearDuration66.63
Ratio of owners equity to gross assets IFRS (5-year summary)Prior1QuarterInstant0.719
Ratio of owners equity to gross assets IFRS (5-year summary)CurrentQuarterInstant0.711
Ratio of owners equity to gross assets IFRS (5-year summary)Prior1YearInstant0.717
Cash flows from used in operating activities IFRS (5-year summary)Prior1YTDDuration26821000000JPY
Cash flows from used in operating activities IFRS (5-year summary)CurrentYTDDuration23595000000JPY
Cash flows from used in operating activities IFRS (5-year summary)Prior1YearDuration58310000000JPY
Cash flows from used in investing activities IFRS (5-year summary)Prior1YTDDuration-28321000000JPY
Cash flows from used in investing activities IFRS (5-year summary)CurrentYTDDuration-11325000000JPY
Cash flows from used in investing activities IFRS (5-year summary)Prior1YearDuration-39456000000JPY
Cash flows from used in financing activities IFRS (5-year summary)Prior1YTDDuration15320000000JPY
Cash flows from used in financing activities IFRS (5-year summary)CurrentYTDDuration-12639000000JPY
Cash flows from used in financing activities IFRS (5-year summary)Prior1YearDuration9432000000JPY
Cash and cash equivalents IFRS (5-year summary)Prior1QuarterInstant135053000000JPY
Cash and cash equivalents IFRS (5-year summary)CurrentQuarterInstant148112000000JPY
Cash and cash equivalents IFRS (5-year summary)Prior1YearInstant149661000000JPY
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember679069600
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember679077200
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant679069600
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant679077200
Number of shares heldCurrentQuarterInstant_No1MajorShareholdersMember230458000
Shareholding ratioCurrentQuarterInstant_No1MajorShareholdersMember0.339

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2024-03-31pass
balance sheet identityconsolidated 2024-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass